Steinbeck G, Bach P, Haberl R
J Am Coll Cardiol. 1986 Oct;8(4):949-58. doi: 10.1016/s0735-1097(86)80440-5.
Programmed ventricular stimulation and ambulatory electrocardiography were performed both before and during oral sotalol therapy in 39 patients with ventricular tachyarrhythmia inducible by programmed stimulation (sustained ventricular tachycardia [n = 31], ventricular fibrillation [n = 3], nonsustained ventricular tachycardia [n = 5]). Oral sotalol was started at 80 mg twice daily and the dose thereafter was then gradually increased until a mean daily dose of 300 mg (range 160-480) was reached. In 12 of 34 patients with inducible sustained ventricular tachycardia or fibrillation the arrhythmia was suppressed; in 19 patients it was not and in 3 the spontaneous arrhythmia recurred. Reproducibly inducible nonsustained ventricular tachycardia was suppressed by sotalol in all five patients with this arrhythmia. Thus, a favorable electrophysiologic response was obtained in 17 (44%) of 39 patients. Arrhythmia suppression correlated with the type of arrhythmia (unsustained or sustained) induced during the control period (p less than 0.05), and nonresponders had a higher incidence of previously ineffective drug trials (p less than 0.05). In 22 patients treated long term with sotalol suppression of arrhythmia inducibility on programmed stimulation predicted freedom from recurrences (16 of 17), whereas continued inducibility indicated drug failure (5 of 5) (p less than 0.005). Serial ambulatory electrocardiograms performed in 37 of the 39 patients did not correlate with the results of electrophysiologic testing. For the patients on long-term treatment, invasive testing was superior to electrocardiographic monitoring in predicting outcome. These data indicate that in daily doses of 160 to 480 mg oral sotalol is a very useful agent in patients presenting with sustained ventricular tachycardia or fibrillation, and its efficacy is fairly well predicted by programmed stimulation.
对39例经程序刺激可诱发室性心律失常(持续性室性心动过速[n = 31]、心室颤动[n = 3]、非持续性室性心动过速[n = 5])的患者,在口服索他洛尔治疗前及治疗期间均进行了程控心室刺激和动态心电图检查。口服索他洛尔起始剂量为每日2次,每次80mg,此后剂量逐渐增加,直至达到平均每日剂量300mg(范围160 - 480mg)。在34例可诱发持续性室性心动过速或心室颤动的患者中,12例心律失常得到抑制;19例未被抑制,3例自发性心律失常复发。索他洛尔可抑制所有5例非持续性室性心动过速患者中可重复诱发的该型心律失常。因此,39例患者中有17例(44%)获得了良好的电生理反应。心律失常抑制与对照期诱发的心律失常类型(非持续性或持续性)相关(p < 0.05),无反应者既往无效药物试验的发生率更高(p < 0.05)。在22例长期接受索他洛尔治疗的患者中,程控刺激时心律失常诱发能力的抑制预示着无复发(17例中的16例),而持续可诱发则表明药物治疗失败(5例中的5例)(p < 0.005)。39例患者中的37例进行的系列动态心电图检查结果与电生理测试结果不相关。对于长期治疗的患者,有创检查在预测预后方面优于心电图监测。这些数据表明,每日剂量为160至480mg时,口服索他洛尔对出现持续性室性心动过速或心室颤动的患者是一种非常有用的药物,其疗效可通过程控刺激较好地预测。